系统性纵隔淋巴结清扫对非小细胞肺癌患者预后的影响

目的：探讨系统性纵隔淋巴结清扫术对非小细胞肺癌患者预后的影响。方法：选择2007年1月至2009年12月在我院住院的124例非小细胞肺癌患者为研究对象，并将其随机分为对照组和实验组，对照组60例患者采用采样式纵隔淋巴结清扫术（med．itational lymphnodesampling，LS）治疗，实验组64例患者采用系统纵隔淋巴结清扫术（systematic meditational lymphadenectomy，SML）治疗。比较两组患者的淋巴结清除总数、淋巴结转移数、淋巴结转移率，通过寿命表法和Kaplan—Meier法比较两组患者的累积3年生存率及中位生存时间。结果：两组比较淋巴结转移率无统计学差异，而与对照组相比，实验组术后并发症发生率明显下降，差异具有统计学意义（P〈0．05）。对照组和实验组患者的中位生存期、3年生存率分别为20．1和24．2个月、18．75％和43．33％，两组比较差异显著，有统计学意义（P〈0．05）。结论：系统性纵隔淋巴结清扫治疗非小细胞肺癌可显著降低患者的淋巴结转移率，并提高患者的3年生存率，延长患者的寿命。

The Effect of Systematic Meditational Lymphadenectomy on the Prognosis of Patients with Non-small Cell Lung Cancer

Objective： To explore the effect of systematic meditational lymphadenectomy in the treatment of non-small cell lung cancer. Methods： We chose 124 patients with non-small cell lung cancer from January 2007 to December 2009 in our hospital, they were all used for sampling meditational lymph node dissections （ meditational lymph node sampling, LS） and regarded as control group, the other 64 patients were treated with system meditational lymph node dissections （systematic meditational lymphadenectomy, SML）. we then compared two groups＇ total number of lymph node removal, the number of lymph node metastasis, lymph node metastatic rate and compared cumulative 3-year survival rate by life table method and median survival time by Kaplan-Meier method. Results： The lymph node metastasis rate of the patients in two groups was no significant difference. Compared with the control group, the patients in experimental group the incidence of postoperative complications was decreased significantly, there was statistical significance （P〈0.05）. The two groups of median survival time, survival rates were respectively 20.1 and 24.2 months, 18.75% and 43.33%. The two groups of median survival time, survival rates were respectively 20.1 and 24.2 months, 18.75% and 43.33%, which had significant difference（P〈0. 05） （P〈0.05）. Conclusion： Systematic meditational lymphadenectomy in the surgical treatment of non-small cell lung cancer reduces the rate of lymph node metastasis, and improves the patients＇ 3 years of survival rate and prolong the life of the patients.